Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares the results of a Phase II study evaluating the safety and efficacy of panobinostat, gemcitabine, busulfan and melphalan (GemBuMel) with autologous stem cell transplant (autoSCT) for patients with high-risk or relapsed/refractory multiple myeloma (NCT02506959). The study was composed of two cohorts - patients who received autoSCT for the first time and patients who had already undergone autoSCT. Overall, the study showed that the therapy improved measurable residual disease (MRD) negativity rates, which was associated with better outcomes. In addition, when compared to a control cohort receiving melphalan alone or with busulfan, patients who received pano/Gem/Bu/Mel had a better progression-free survival (PFS). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
